A Prospective Non-randomised Trial of Chemotherapy and Radiotherapy for Osteolymphoma
Patients with non-Hodgkin's lymphoma arising primarily in bone have been studied using a
number of different names making literature searching difficult. The term Osteolymphoma has
been proposed to make searching easier in the future. Patients in this study undergoing
staging which includes isotope bone scanning and PET scanning where available. Eligible
patients then undergo treatment with three cycles of CHOP chemotherapy at conventional doses
and shrinking field radiotherapy to a total of 45 Gy. Monoclonal antibodies are not included
as good results have been obtained without using them. After treatment the patients are
regularly monitored. The trial is presented twice per year at the meetings of TROG, ALLG and
AROLG.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall Survival. The time from registration to the date of death
Main analysis when accrual is complete at approx. 10 years.
No
David Christie, FRANZCR
Study Chair
East Coasr Cancer Centre
Australia: Human Research Ethics Committee
TROG 99.04
NCT00141648
September 2000
February 2008
Name | Location |
|---|
